International Journal of Clinical Oncology

OCT 21, 2026 · JOURNAL ARTICLE

Electronic patient-reported outcome monitoring and quality of life during later-line nivolumab therapy for advanced gastric cancer

International Journal of Clinical Oncology

Abstract Background Health-related quality of life (HRQoL) often deteriorates during later-line treatment for advanced gastric cancer. Although nivolumab monotherapy has been an es

OCT 21, 2026 · JOURNAL ARTICLE

Re-evaluating the neutropenia–survival paradigm in irinotecan-based therapy for advanced gastric cancer: post-hoc analysis of the RINDBeRG trial

International Journal of Clinical Oncology

Abstract Background Chemotherapy-induced neutropenia (CIN) has been considered a favorable prognostic marker across multiple cytotoxic regimens for gastrointestinal malignancies. H

OCT 13, 2026 · JOURNAL ARTICLE

Association between fat-free mass index and severe locomotive syndrome in patients with cancer: sex-specific cutoff values

International Journal of Clinical Oncology

Abstract Background Locomotive syndrome (LS) is a clinical condition used to describe reduced mobility caused by musculoskeletal dysfunction and is highly prevalent among patients

OCT 3, 2026 · JOURNAL ARTICLE

Serum albumin is associated with immune-related hypothyroidism and treatment continuity in non-small cell lung cancer

International Journal of Clinical Oncology

Abstract Background Immune checkpoint inhibitors (ICIs) are a standard treatment for advanced non-small cell lung cancer (NSCLC), but clinically practical predictors of immune-rela

SEP 24, 2026 · JOURNAL ARTICLE

Efficacy and biomarker analysis for nivolumab in cancer of unknown primary: results from an investigator-initiated expanded access program

International Journal of Clinical Oncology

Abstract Background Cancer of unknown primary (CUP) remains a challenging malignancy with a poor prognosis. Although immune checkpoint inhibitors have shown activity in CUP, availa

AUG 11, 2026 · JOURNAL ARTICLE

Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis

International Journal of Clinical Oncology

Rigorous phase 3 pooled analysis demonstrating a clinically meaningful OS benefit (HR 0.46) with durable 5-year survival gains in a population with high unmet need and poor prognosis, though sample size in the Japanese subgroup is modest.